In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan), a contrast agent for magnetic resonance imaging.
about
Caco-2 cell acquisition of dietary iron(III) invokes a nanoparticulate endocytic pathwayAssessing the efficacy of nano- and micro-sized magnetic particles as contrast agents for MRI cell trackingEffects of Iron-Oxide Nanoparticle Surface Chemistry on Uptake Kinetics and Cytotoxicity in CHO-K1 Cells.Superparamagnetic iron oxide nanoparticles: amplifying ROS stress to improve anticancer drug efficacy.Use of ultrasmall superparamagnetic iron oxide particles for imaging carotid atherosclerosis.Hollow superparamagnetic iron oxide nanoshells as a hydrophobic anticancer drug carrier: intracelluar pH-dependent drug release and enhanced cytotoxicity.Poly[2-(methacryloyloxy)ethylphosphorylcholine]-coated iron oxide nanoparticles: synthesis, colloidal stability and evaluation for stem cell labelling.The internalization pathway, metabolic fate and biological effect of superparamagnetic iron oxide nanoparticles in the macrophage-like RAW264.7 cell.Engineered biocompatible nanoparticles for in vivo imaging applications.Rapid and efficient cell labeling with a MRI contrast agent by electroporation in the presence of protamine sulfate.Efficacy and Durability in Direct Labeling of Mesenchymal Stem Cells Using Ultrasmall Superparamagnetic Iron Oxide Nanoparticles with Organosilica, Dextran, and PEG Coatings.Dual-modality, fluorescent, PLGA encapsulated bismuth nanoparticles for molecular and cellular fluorescence imaging and computed tomography.Liver and brain imaging through dimercaptosuccinic acid-coated iron oxide nanoparticles.Intravenous Irons: From Basic Science to Clinical PracticeMagneto-Thermal Metrics Can Mirror the Long-Term Intracellular Fate of Magneto-Plasmonic Nanohybrids and Reveal the Remarkable Shielding Effect of Gold
P2860
Q35053949-B7A960C9-E06D-4156-910A-0AAAA4299B90Q35193933-651FD006-3E9F-433C-93ED-1886548E1E28Q36512500-3A0D3B4F-B305-4605-8836-001F428622E6Q36619072-6E8F216A-E002-4B0E-A563-B86E57314A5AQ38595475-1F1E7169-2E94-4076-9FE4-6F62151F3DEBQ39296951-9786DFD2-E8E1-4FAF-BDE5-FD163E498307Q39297129-5984AF22-7895-4540-9CD7-AA9FCCECE8D6Q39472913-418D4CA4-F8A2-47D9-9537-C4D4F6C13245Q39648404-9EF084F1-CB4A-4F33-864A-C869CD579EA1Q39866576-CC1634A6-AC6E-4E0C-8A2E-D3F89DA1F0C3Q42117511-C3746C51-86B5-41D9-ACC9-8781A3C8B6A0Q42558508-15C6000A-FA8B-4E39-A4EF-349F68DBE0B1Q43098424-9C0DF285-C932-4744-9BD0-2B07D4E44626Q57167424-CFF132B5-C6DB-4C9E-B5C7-E01D47FDF866Q57559225-794F919D-DBE1-43B3-8CC9-CD6509464362
P2860
In vitro stability analyses as a model for metabolism of ferromagnetic particles (Clariscan), a contrast agent for magnetic resonance imaging.
description
2002 nî lūn-bûn
@nan
2002 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
In vitro stability analyses as ...... or magnetic resonance imaging.
@ast
In vitro stability analyses as ...... or magnetic resonance imaging.
@en
type
label
In vitro stability analyses as ...... or magnetic resonance imaging.
@ast
In vitro stability analyses as ...... or magnetic resonance imaging.
@en
prefLabel
In vitro stability analyses as ...... or magnetic resonance imaging.
@ast
In vitro stability analyses as ...... or magnetic resonance imaging.
@en
P2093
P1476
In vitro stability analyses as ...... or magnetic resonance imaging.
@en
P2093
Inger Oulie
Per Christian Sontum
Tore Skotland
P304
P356
10.1016/S0731-7085(01)00592-1
P577
2002-04-01T00:00:00Z